Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.420
-0.040 (-2.74%)
At close: Feb 21, 2025, 4:00 PM
1.490
+0.070 (4.93%)
After-hours: Feb 21, 2025, 4:27 PM EST
Fractyl Health Revenue
Fractyl Health had revenue of $14.00K in the quarter ending September 30, 2024, a decrease of -61.11%. This brings the company's revenue in the last twelve months to $97.00K, down -14.16% year-over-year. In the year 2023, Fractyl Health had annual revenue of $120.00K.
Revenue (ttm)
$97.00K
Revenue Growth
-14.16%
P/S Ratio
704.13
Revenue / Employee
$951
Employees
102
Market Cap
68.30M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 120.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GUTS News
- 22 days ago - Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 - GlobeNewsWire
- 2 months ago - Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 2 months ago - Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 3 months ago - Fractyl Health to Participate in the Upcoming December Conferences - GlobeNewsWire
- 3 months ago - Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 - GlobeNewsWire
- 4 months ago - Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024 - GlobeNewsWire